Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma
Related Experiment Video
Updated: Sep 27, 2025
Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
Published on: October 24, 2016
Xieling Yin1, Hongjian Chen1, Shi Chen1
1Department of Hepatobiliary and Pancreatic Surgery, Tumor Hospital Affiliated To Nantong University, China.
Background:
Liver hepatocellular carcinoma (LIHC) is the second leading cause of tumor-related death in the world. Carvacrol was also found to inhibit multiple cancer types. Here, we proposed that Carvacrol inhibited LIHC.
Methods:
We used MTT assay to determine the inhibition of Carvacrol on LIHC cells. BATMAN-TCM was used to predict targets of Carvacrol. These targets were further screened by their survival association and expression in cancer using TCGA data. The bioinformatic screened candidates were further validated in in vitro experiments and clinical samples. Finally, docking models of the interaction of Carvacrol and target protein were conducted.
Results:
Carvacrol inhibited the viability of LIHC cell lines. 40 target genes of Carvacrol were predicted, 8 of them associated with survival. 4 genes were found differentially expressed in LIHC vs. normal liver. Among these genes, the expression of SLC6A3 and SCN4A was found affected by Carvacrol in LIHC cells, but only SLC6A3 correlated with the viability inhibition of Carvacrol on LIHC cell lines. A docking model of the interaction of Carvacrol and SLC6A3 was established with a good binding affinity. SLC6A3 knockdown and expression revealed that SLC6A3 promoted the viability of LIHC cells.
Conclusion:
Carvacrol inhibited the viability of LIHC cells by downregulating SLC6A3.
Insights
Carvacrol, a natural compound, effectively inhibits liver hepatocellular carcinoma (LIHC) cell viability. This inhibition occurs by downregulating the expression of the SLC6A3 gene, a key promoter of LIHC cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Liver hepatocellular carcinoma (LIHC) is a significant global health concern, ranking as the second leading cause of cancer-related mortality.
- Carvacrol, a naturally occurring monoterpenoid phenol, has demonstrated inhibitory effects against various cancer types.
- This study investigates the potential of carvacrol as a therapeutic agent against LIHC.
Purpose of the Study:
- To determine the inhibitory effect of carvacrol on the proliferation of LIHC cells.
- To identify and validate the molecular targets of carvacrol involved in LIHC progression.
- To elucidate the mechanism by which carvacrol exerts its anti-cancer effects in LIHC.
Main Methods:
- Cell viability was assessed using the MTT assay.
- Potential carvacrol targets were predicted using BATMAN-TCM and further analyzed with TCGA data for survival and expression correlations.
- Bioinformatically identified targets were validated through in vitro experiments and analysis of clinical samples, complemented by molecular docking studies.
Main Results:
- Carvacrol significantly reduced the viability of LIHC cell lines.
- Bioinformatic analysis predicted 40 target genes, with 8 showing survival association and 4 exhibiting differential expression in LIHC.
- SLC6A3 was identified as a key target, with carvacrol downregulating its expression, which correlated with reduced LIHC cell viability. Molecular docking confirmed a strong binding affinity between carvacrol and SLC6A3.
Conclusions:
- Carvacrol demonstrates potent anti-proliferative effects against LIHC cells.
- The study identifies SLC6A3 as a critical mediator of carvacrol's anti-cancer activity in LIHC.
- Carvacrol inhibits LIHC progression primarily through the downregulation of SLC6A3, highlighting its therapeutic potential.
